Pfizer (PFE) Receiving Somewhat Favorable Press Coverage, Analysis Finds
Headlines about Pfizer (NYSE:PFE) have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 6,000 news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pfizer earned a news impact score of 0.86 on their scale. InfoTrie also assigned news headlines about the biopharmaceutical company an news buzz score of 5 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company’s share price in the near future.
These are some of the headlines that may have impacted Pfizer’s ranking:
- Peninsula drug maker to pay $360M to settle Justice Department claims (feeds.bizjournals.com)
- Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx (finance.yahoo.com)
- Pfizer (PFE) Stock Moves -1.78%: What You Should Know (finance.yahoo.com)
- Today’s Research Reports on Trending Tickers: Pfizer and Merck & Co. (finance.yahoo.com)
- Somewhat Positive Media Coverage Somewhat Likely to Impact Pfizer (PFE) Share Price (americanbankingnews.com)
NYSE:PFE opened at $44.98 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.15 and a current ratio of 1.43. Pfizer has a 52-week low of $33.20 and a 52-week high of $46.47. The firm has a market cap of $268.71 billion, a P/E ratio of 16.97, a P/E/G ratio of 2.25 and a beta of 0.88.
The business also recently disclosed a quarterly dividend, which was paid on Monday, December 3rd. Investors of record on Friday, November 9th were paid a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.02%. Pfizer’s payout ratio is 51.32%.
Several analysts have issued reports on PFE shares. Barclays set a $40.00 target price on Pfizer and gave the company a “neutral” rating in a research note on Wednesday, August 29th. Atlantic Securities restated a “buy” rating and issued a $54.00 target price on shares of Pfizer in a research note on Tuesday, November 27th. Deutsche Bank set a $45.00 target price on Pfizer and gave the company a “buy” rating in a research note on Tuesday, August 21st. Cantor Fitzgerald set a $53.00 target price on Pfizer and gave the company a “buy” rating in a research note on Thursday, November 8th. Finally, Morgan Stanley set a $45.00 target price on Pfizer and gave the company a “buy” rating in a research note on Thursday, September 13th. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $43.27.
In related news, major shareholder Pfizer Inc acquired 55,556 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The shares were bought at an average cost of $18.00 per share, for a total transaction of $1,000,008.00. Following the purchase, the insider now owns 21,976,484 shares in the company, valued at approximately $395,576,712. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
See Also: Do stock splits help investors?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.